Cart
sales@molnova.com
BMS-2
CAS No. 888719-03-7
BMS-2( —— )
Catalog No. M21662 CAS No. 888719-03-7
BMS-2 is a Met/Flt-3/VEGFR2 tyrosine kinase inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 179 | In Stock |
|
| 2MG | 90 | In Stock |
|
| 5MG | 151 | In Stock |
|
| 10MG | 242 | In Stock |
|
| 25MG | 454 | In Stock |
|
| 50MG | 642 | In Stock |
|
| 100MG | 927 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBMS-2
-
NoteResearch use only, not for human use.
-
Brief DescriptionBMS-2 is a Met/Flt-3/VEGFR2 tyrosine kinase inhibitor.
-
DescriptionBMS-2 is a Met/Flt-3/VEGFR2 tyrosine kinase inhibitor.
-
In Vitro——
-
In VivoAnimal Model:MiceDosage:5, 10 mg/kg Administration:IV, POResult:Showed extensive extravascular distribution and a favorable half-life.Animal Model:Nude mice Dosage:6.25, 12.5, 25 and 50 mg/kg Administration:PO, once a day Result:Showed antitumor activity in dose-dependet.
-
Synonyms——
-
PathwayAngiogenesis
-
Targetc-Met/HGFR
-
RecptorMet|FLT3|VEGFR2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number888719-03-7
-
Formula Weight458.42
-
Molecular FormulaC25H16F2N4O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (218.14 mM)
-
SMILESFc1ccc(cc1)-n1cccc(C(=O)Nc2ccc(Oc3ccnc4[nH]ccc34)c(F)c2)c1=O
-
Chemical Name1-(4-Fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[23-b]pyridin-4-yloxy)phenyl]-2-oxopyridine-3-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
LMTK3-IN-1
Lmtk3-in-1 is a potent ATP-competitive lemur tyrosine kinase 3 (LMTK3) (Kd=2.5 μM) inhibitor that degrades LMTK3 through the ubiquitin proteasome pathway.
-
MK-8033 hydrochlorid...
MK-8033 is a potent, specific, dual c-Met/Ron kinases inhibitor with IC50 of 1/7 nM.
-
Telisotuzumab
Telisotuzumab(ABT-700) is a humanized recombinant antibody targeting the therapeutic hepatocyte growth factor receptor (MET) with high affinity for c-Met.Telisotuzumab has inhibitory effects on c-Met signaling and antitumor activity.
